Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings
Completed
- Conditions
- Diffuse Large B-cell Lymphoma
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1031
- Registration Number
- NCT05918809
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT05900141
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
Completed
- Conditions
- Chronic Myeloid Leukaemia
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 555
- Registration Number
- NCT05893836
- Locations
- 🇬🇧
Haematological Malignancy Research Network, York, United Kingdom
Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
Phase 3
Completed
- Conditions
- Primary Hypercholesterolemia or Mixed Dyslipidemia
- Interventions
- Drug: Matching Placebo for Inclisiran
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 207
- Registration Number
- NCT05888103
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Phase 3
Recruiting
- Conditions
- Follicular Lymphoma (FL)
- Interventions
- Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cyclesDrug: Lymphodepleting chemotherapyOther: Corticosteroids and/or Radiation (Bridging therapy)
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 108
- Registration Number
- NCT05888493
- Locations
- 🇺🇸
TRIHEALTH Good Samarithan Hospital, Cincinnati, Ohio, United States
🇨🇳Novartis Investigative Site, Taipei, Taiwan
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
Phase 2
Active, not recruiting
- Conditions
- Primary Immune Thrombocytopenia (ITP)
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05885555
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Cente, Boston, Massachusetts, United States
🇬🇧Novartis Investigative Site, London, United Kingdom
Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
Completed
- Conditions
- Melanoma
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17517
- Registration Number
- NCT05874817
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Adherence and Persistence to Inclisiran Among Early Users in Germany
Completed
- Conditions
- High Levels of Low-density Lipoprotein Cholesterol
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1109
- Registration Number
- NCT05870657
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure
Withdrawn
- Conditions
- Heart Failure
- Interventions
- Other: sacubitril/valsartan
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05870709
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Phase 1
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05870579
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath